Sareum share price climbs on US patent grant announcement

The share price of AIM-listed specialist cancer drug discovery business Sareum Holdings jumped sharply on Thursday after the company announced that a patent was due to be awarded in the US for one of its key drug discovery inventions.

By MoneyWeek

published 7 February 2013

in Features

The patent, which is expected on February 19th, relates to compounds that inhibit or modulate the activity of kinase enzymes.

MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free

https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

SKIL is the acronym used to describe Sareum Kinase Inhibitor Library. It is the company's drug discovery technology platform.

Sareum's Chief Scientific Officer, Dr John Reader, said: "This first grant of a patent for Sareum significantly strengthens our patent portfolio, and enhances our negotiating position with potential licensing and collaboration partners."

Sareum's share price was up 13.70% to 2.08p at 08:39 on Thursday.

MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.